8.630USD-2.71%Mkt Cap: —P/E: —1d ago
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-u…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value1.75B $
Revenue (TTM)335.41M $
Gross Profit290.38M $
Net Income (TTM)-17.16M $
Revenue/Share1.993 USD
Last Price8.630 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees435
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS98422E1038
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA35.83
EV/Revenue5.21
P/S—
P/B-155.19
EPS (TTM)-1.42
EPS (Forward)—
52W Range
8.6251% of range9.000
52W High9.000 USD
52W Low8.625 USD
Profitability
Gross Margin86.57%
Oper. Margin5.62%
EBITDA Margin14.54%
Profit Margin-5.12%
ROE—
ROA6.13%
Growth
Revenue Growth28.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF56.61M $
CapEx (TTM)—
FCF Margin15.64%
FCF Yield—
Net Debt167.69M $
Net Debt/EBITDA3.44
Balance Sheet
Debt/Equity—
Current Ratio1.45
Quick Ratio0.95
Book Value/Sh-0.0560 USD
Cash/Share0.6680 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float175.99M
Insiders3.12%
Institutions59.94%
Technical
SMA 502.681 (+221.9%)
SMA 2002.360 (+265.7%)
Beta0.85
S&P 52W Chg20.80%
Avg Vol (30d)1.30K
Avg Vol (10d)7.56K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—